COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0RB6L
|
|||
Drug Name |
rhACE2
|
|||
Synonyms |
recombinant human ACE2; APN01
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN angiotensin-converting enzyme 2 (ACE2) | Target Info | Inhibitor | [2] |
Excessive ACE2 can competitively bind with SARS-CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system (RAS) to protect the lung from injury. Thus rhACE2 is in the clinical reasearch for COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04335136) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. U.S. National Institutes of Health. | |||
2 | ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.